Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Summary of premarket trading halts and resumptions on April 28th
28/04/2026
On April 28th, *ST Guohua, Zhunyou Company, Tongde Chemical, and Maiquel were temporarily suspended; *ST Xifa, ST Palm, *ST Bangjie, and Zhenai Meijia resumed trading.
Latest
2 m ago
Multiple departments issue safety tips for the 2026 "May Day" holiday.
3 m ago
Storage chip sector stabilizes and warms up, Siaten shares hit the limit up.
3 m ago
The Sci-Tech Innovation 50 Index has increased by 1%.
4 m ago
According to AI Flash News, Open Source Securities released a research report on April 28, giving Caitong Securities (601108.SH) a "buy" rating. The main reasons for the rating include: 1) Doubling of first quarter net profit growth, high year-on-year growth in investment income; 2) Brokerage year-on-year growth, investment banking under pressure year-on-year, Caitong Asset Management to contribute 19% of profit by 2025; 3) Core joint-stock subsidiary contributes 17% of profit, first quarter investment income increases year-on-year. (Everyday Economic News)
4 m ago
According to AI Express, Open Source Securities released a research report on April 28, giving Xin Qi Eyedrops (300573.SZ) a "buy" rating. The reasons for the rating mainly include: 1) Building a series of ophthalmic drug varieties, steadily advancing the new drug pipeline; 2) Rapid growth in performance, with the low-concentration atropine expected to continue to increase in volume by 2026, maintaining a "buy" rating. (Daily Economic News)
See all latest